Latest news with #Travelan
Yahoo
17-07-2025
- Business
- Yahoo
Immuron - FY25 global sales exceed projection, up 49% on prior year
Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior year June 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) Palumbo, Chief Commercial Officer, said, 'Immuron has exceeded sales projections and achieved record FY25 sales of A$7.3 million, with growth just shy of 50% on last year. In FY25, we set out to make Travelan the must-have travel essential for consumers and retailers. This is a fantastic result, supporting our clear growth strategy. Australia, on the back of increased consumer engagement and a clear pharmacy visibility program, achieved annual sales of A$5.2 million, growth of 40% on last year. Travelan is now one of the fastest growing brands in pharmacy in Australia. Our North American business continues to produce record results with strong USA sales to Amazon with improved, more targeted communication focused on the benefits of Travelan driving more users into the brand. This, together with establishing good distribution of Travelan in Canada, resulted in North American sales of A$2 million, growth of 76% on last year. We have achieved record Travelan sales in all markets. In FY26, we will invest to grow in North America while continuing the momentum in Australia.' This release has been authorised by the directors of Immuron Limited. Steven LydeamoreChief Executive Officersteve@ About Travelan®Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler's diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler's Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler's Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection. About Traveler's diarrheaTraveler's Diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. About ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. For more information visit: FORWARD-LOOKING STATEMENTS: This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A photo accompanying this announcement is available at: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
News.com.au
17-07-2025
- Business
- News.com.au
Health Check: Immuron shares bust out for a ‘run' on strong Travelan sales
Immuron shares surge more than 30% on robust sales of the company's traveller's trots prophylactic Visionflex turns cash flow positive In Tetra-theory, this one's worth a lot more Wake up folks! It's mid-July but there's still only a trickle of June quarter reports emanating from the life sciences sector. We blame the school holidays. In the meantime companies prefer informal, unaudited updates. In this vein, Immuron (ASX:IMC) reports Travelan sales of $7.3 million for the year to June 2025, 49% higher. June quarter sales came in at $2 million, up 55%, Based on the goodness of cow's milk, Travelan is an over-the-counter immune supplement targeting gastrointestinal pathogens. Unlike most traveller's diarrhoea aids, it tackles the root of the problem rather than merely bunging it up. Travelan has been around for two decades, but the brand got a bit tired and management decided it was time to bolster promotion. In Australia, a 'clear pharmacy visibility program' helped to boost sales to $5.2 million, 40% higher. North American sales grew 76% to $2 million, with strong Amazon sales driving demand. Meanwhile medical pot supplier Little Green Pharma (ASX:LGP) reports June quarter revenue of $9.1 million, up 20%, and receipts of $12 million (50% higher). Little Green also has positive cash flow of $500,000, taking the cash balance to $2.5 million. Earlier, Little Green disclosed revenue of $36.8 million for the year to March 2025, with a $3.3 million net profit. A Visionflex turnaround is more than a remote prospect In news from the boondocks, remote healthcare outfit Visionflex (ASX:VFX) reports a June quarter revenue surge on the back of new contracts, while also turning cash flow positive. Relative to the March quarter, revenue grew 148% to $2 million. On a year-on-year basis, the turnover was 14% higher. The company managed cash flow of $300,000, compared with a $900,000 of March quarter outflows. Visionflex provides proprietary software and hardware – such as examination cameras – to remotely diagnose patients, typically in far-flung communities. During the quarter, Visionflex inked a $1 million deal with the Medibank Private (ASX:MPL) owned Amplar Health. A homecare provider, Amplar operates 30 sites. It also signed up a 'leading ASX mining company' to roll out the gear across 13 medical centres and one aircraft. Visionflex says 19% of its revenue is now recurring, which 'aligns with the company's focus on growing a more predictable, higher margin revenue base.' This quarter, the company hopes to launch a tailored homecare product. Given 900 providers service this sector with more than 2300 services, the company reckons it's tapping a rich vein. Trivarx says its depression trial is fully enrolled … TrivarX (ASX:TRI) says it has enrolled ten patients in its veterans' mental health trial and is on track to achieve its target of 30 participants. A mental health technology company, TrivarX pioneers the use of objective measures to screen for mental health conditions and detect them early. The study deploys electrocardiogram (ECG) screening to detect current major depressive episodes in veterans with suspected sleep apnoea. The trial is underway at the West Los Angeles VA Medical Center. There, participants undergo an overnight, multi-parameter sleep study and neuropsychiatric interview. The ECG algorithm extends Trivarx's lead asset, its AI-driven MEB-001 device. Trivarx expects to complete the study by mid-September. ... while Clarity also puts out the 'full house' shingle In other trial news, radiopharmaceutical developer Clarity Pharmaceuticals (ASX:CU6) says a 50 patient, phase II study of its prostate cancer imaging candidate is fully enrolled. The study evaluates Clarity's copper-isotope based agent 64Cu-SAR-bisPSMA, compared to the standard-of-care gallium-based alternative. In nuclear medicine, there are isotopes and isotopes ... Carried out at Sydney's St Vincent's Hospital, the investigator-initiated study enrols patients with low prostate-specific antigen (PSA). These patients are candidates for "curative salvage therapies". 'The high volume of patients imaged in recent months at a single site reflects the high unmet need for more effective diagnostic tools for men with rising PSA following radical prostatectomy,' Clarity executive chair Dr Alan Taylor says. The company expects trial results 'in coming months'. Tetratherix shares 'worth 58% more' Tetratherix (ASX:TTX) shares have surged a healthy 22% since the wound management company listed on June 30, but broker Morgans reckons there's another 58% of upside. The company has developed Tetramatrix, a fluid-like polymer injected into the relevant bodily area. The body temperature results in the material setting to a gum-like state that surgeons can shape to suit the purpose. The material doesn't spark a foreign body response and is reabsorbed when it has done its job. Tetratherix initially is focusing on bone regeneration, tissue spacing, and tissue healing – a US$6.8 billion market. The company expects FDA clearance for the dental product in late 2026, while the orthopedic and oncology spacing offerings should be green lit in late 2028. Morgans believes the company will be profitable in the 2027-28 year but expects a current year deficit of $10.8 million on revenue of $1 million. Morgans values the stock at $5.72 – almost double the $2.88 issue price in the $25 million raising. The firm was a joint manager for the IPO. Pacific Edge rattles the can Meanwhile, diagnostics house Pacific Edge (ASX:PEB) has launched a share purchase plan to raise up to NZ$5 million. This follows the company's June 3 conditional placement of NZ$16.1 million, NZ$1.1 million more than planned. The raising has been done at 10 NZ cents a share, an unusual 22% premium to the prevailing price. In April the company's Cxbladder test was kicked off the US Medicare coverage rota. The company says the funds partly will support operations for another 12 months without Medicare coverage, while management pursues reinstatement.
